The Basel-based multinational, which supplies the pharma industry, expects the CHF500 million ($522 million) facility to be ready in 2026.
The site in Stein, northern Switzerland, will be dedicated to the specialised tasks of filling vials with vaccine and finishing the packaging for distribution (known as fill and finish in the industry). It is a process that is often outsourced in the pharma sector and known to cause bottlenecks in the availability of new vaccines.
“Combined with our strong drug substance manufacturing footprint, the new facility will enable us to provide customers with an integrated end-to-end offering across their entire product life cycle,” said CEO Pierre-Alain Ruffieux on Friday.
The new facility will be more energy efficient and have a photovoltaic roof. It will be built on the same campus as Lonza’s clinical drug product facility in Stein. The company also manufactures drugs in Basel and Visp, as well as in Guangzhou, China.
Popular Stories
More
Climate adaptation
Why Switzerland is among the ten fastest-warming countries in the world
Has your continent reached its peak or is there still potential for economic growth?
Some regions of the world are on an upward trajectory with the promise of a steadily improving future. Where do you live? And in which direction is your region or continent developing?
Swiss president kicks off National Day celebrations on Rütli meadow
This content was published on
Several hundred people gathered on the Rütli in central Switzerland at midday on Friday to celebrate the national Swiss holiday, before Karin Keller-Sutter addressed the crowd.
US sets deadline for Novartis and other pharma firms to lower prices
This content was published on
US President Donald Trump says he has sent letters to Swiss giant Novartis and other pharma firms calling for lower drug prices in the United States – or face retaliation.
Around 25,000m3 of rockfall registered in Swiss village of Brienz
This content was published on
More rock has come loose in the eastern Swiss village of Brienz than initially assumed following rainfall last weekend, said a new situation report published on Friday.
Swiss government reacts with ‘great regret’ to new US tariffs
This content was published on
The Swiss government says it will continue to strive for a negotiated solution after the United States imposed 39% tariffs on the Alpine country.
Switzerland testing AI tools to make scarecrows more effective
This content was published on
The Swiss agricultural research centre Agroscope is testing an AI system to more effectively prevent damage to agricultural crops caused by crows and rooks.
UN in Geneva calls for reform of tariffs on plastics
This content was published on
The United Nations is calling for a reform of customs tariffs on plastics, which are lower than those imposed on alternatives, ahead of negotiations for a treaty to limit plastic pollution.
Two robots play hide-and-seek in space with Swiss help
This content was published on
Robots developed separately have worked together at the International Space Station (ISS) for the first time, helped in part by a control centre in Switzerland.
Giant Swiss flag torn by the wind at the foot of mountain
This content was published on
A giant Swiss flag tore as it was rolled out on a grassy slope at the foot of a mountain ahead of August 1 National Day celebrations.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Pandemic reveals Switzerland’s weak spot in securing foreign talent
This content was published on
Switzerland is increasingly being challenged as a business location because of immigration restrictions. Could the pandemic be a turning point?
Lonza to double production of Covid-19 vaccine at Swiss plant
This content was published on
The Swiss firm will add three more production lines to its plant as part of a larger effort to boost Moderna’s global supply of vaccine doses.
Covid vaccines: how to end the wait for billions of people
This content was published on
A waiver on intellectual property rights could be the key to getting more Covid drugs and vaccines to the developing world. But it's controversial.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.